Multiple Sclerosis Therapeutics, Second Edition

Part I: Introduction. Aspects of Multiple Sclerosis that Relate to Clinical Trial Design and Treatment. Part II: Clinical Trial Methodology. Measures of Impairment and Disability. Assessment of Neuropsychological Function. Health-related Quality of Life Assessment in Multiple Sclerosis. Magnetic Resonance Imaging in Multiple Sclerosis: an Overview. Measures of Gadolinium Enhancement. Measures of Magnetization Transfer. Measures of T1 and T2 Relaxation. Measurement of CNS Atrophy. Measures to Quantify Axonal Damage In Vivo Based on Magnetic Resonance Spectroscopy. Functional Imaging in Multiple Sclerosis. The Use of Cost Analyses to Improve our Understanding of Therapeutic Trade-offs for Multiple Sclerosis. Ethical Considerations in Multiple Sclerosis Clinical Trials. The Process of Drug Development and Approval in the United States, European Union, and Canada. Sponsors, Monitoring Committees, and Investigators: the Investigator's Perspective. Guidelines for Clinical Trials of New Therapeutic Agents in Multiple Sclerosis: Reporting Extended Results from Phase III Clinical Trials. The Failed Clinical Trial. The Challenge of Long-term Studies in MS: Use of Pooled Data, Historical Controls, and Observational Studies to determine efficacy. Part III: Clinical Trials of Disease Modifying Therapy. Emerging Concepts of Pathogenesis: Relationship to MS Therapies. Interferons in Relapsing Remitting MS. Interferons in Secondary Progressive MS. Biologic Mechanisms of Action of Interferons in MS. Glatiramer Acetate. Mitoxantrone. Intravenous Immunoglobin to Treat Multiple Sclerosis. Therapeutic Plasma Exchange for Multiple Sclerosis. Methylprednisolone. Cyclophosphamide Treatment of Multiple Sclerosis. Treatment of Multiple Sclerosis by Hematopoietic Stem Cell Transplantation. Emerging Disease-modifying Therapies. Combination Therapies in Multiple Sclerosis. Sex Hormones and Other Pregnancy Related Factors with Therapeutic Potential in Multiple Sclerosis. Complementary and Alternative Treatments in Multiple Sclerosis. Part IV: Therapy in Clinical Practice. Use of Disease-modifying Drug Therapy for Relapsing Forms of MS in Clinical Practice. Primary Progressive MS. Fatigue. Management of Spasticity in Multiple Sclerosis. Bladder and Sexual Dysfunction. Treatment of Disorders of Mood and Affect. Pain and Paroxysmal Disorders. Tremor. Management of Cognitive Impairment in MS. Rehabilitation in Multiple Sclerosis Patients Sclerosis that Relate to Clinical Trial Design and Treatment. Part II: Clinical Trial Methodology. Measures of Impairment and Disability. Assessment of Neuropsychological Function. Health-related Quality of Life Assessment in Multiple Sclerosis. Magnetic Resonance Imaging in Multiple Sclerosis: an Overview. Measures of Gadolinium Enhancement. Measures of Magnetization Transfer. Measures of T1 and T2 Relaxation. Measurement of CNS Atrophy. Measures to Quantify Axonal Damage In Vivo Based on Magnetic Resonance spectroscopy. Functional Imaging in Multiple Sclerosis. Bodily Fluid Markers for Disease Course and Activity. The Use of Cost Analyses to Improve our Understanding of Therapeutic Trade-offs for Multiple Sclerosis. Ethical Considerations in Multiple Sclerosis Clinical Trials. The Process of Drug Development and Approval in the United States, European Union, and Canada. Sponsors, Monitoring Committees, and Investigators: the Investigator's Perspective. Guidelines for Clinical Trials of New Therapeutic Agents in Multiple Sclerosis: Reporting Extended Results from Phase III Clinical Trials. The Failed Clinical Trial. The Challenge of Long-term Studies in MS: Use of Pooled Data, Historical Controls, and Observational Studies to Determine Efficacy. Part III Clinical Trials of Disease Modifying Therapy. Emerging Concepts of Pathogenesis: Relationship to MS Therapies. Interferons in Relapsing Remitting MS. Interferons in Secondary Progressive MS. Biologic Mechanisms of Action of Interferons in MS.